Low Expression of DDX60 Gene Might Associate with the Radiosensitivity for Patients with Breast Cancer

Low Expression of DDX60 Gene Might Associate with the Radiosensitivity for Patients with Breast Cancer
复制标题

DDX60基因低表达可能与乳腺癌患者的放射敏感性有关

DOI:
10.1155/2020/8309492
复制
发表时间:
2020-07-20
影响因子:
--
通讯作者:
Tang, Zaixiang
Tang, Zaixiang
中科院分区:
医学3区
文献类型:
--
作者:
Xin, Dongrun;Liu, Jingfang;Tang, Zaixiang

文献摘要

被引文献

相似文献

DEXD/H box helicase 60(DDX 60)是一种新型的DEAD-box RNA helicase,在病毒感染后被诱导表达。它可能通过促进RIG-I样受体介导的信号转导参与抗病毒免疫。此外,已有研究表明DDX 60的表达与肿瘤发生有关,但在乳腺癌中尚缺乏相关研究。本研究利用TCGA数据库中的乳腺癌患者信息进行统计分析,发现DDX 60低表达的乳腺癌患者具有放射敏感性。比较放疗组与非放疗组,对于DDX 60低表达的患者,在训练和验证数据集中,放疗的校正风险比(HR)值分别为0.244(0.064-0.921)和0.199(0.062-0.646),p值分别为0.040和0.007。然而,对于DDX 60高表达的患者,校正的风险比(HR)值分别为3.582(0.627-20.467)和2.421(0.460-12.773),p值分别为0.054和0.297。提示DDX 60的表达与乳腺癌个体化放疗敏感性密切相关。
DEXD/H box helicase 60 (DDX60) is a new type of DEAD-box RNA helicase, which is induced to express after virus infection. It might involve in antiviral immunity by promoting RIG-I-like receptor-mediated signal transduction. In addition, previous studies had shown that the expression of DDX60 is related to cancer, but there was still a lack of relevant research in breast cancer. In this study, we used the information of patients with breast cancer in the TCGA database for statistical analysis and found that the breast cancer patients with low expression of DDX60 exhibited radiosensitivity. Comparing the radiotherapy groups with the nonradiotherapy groups, for patients with low expression of DDX60, the adjusted hazard ratio (HR) values for radiotherapy were 0.244 (0.064–0.921) and 0.199 (0.062–0.646) in the training and validation datasets, with the p values 0.040 and 0.007, respectively. However, for patients with high expression of DDX60, the adjusted hazard ratio (HR) values were 3.582 (0.627–20.467) and 2.421 (0.460–12.773), with the p values 0.054 and 0.297, respectively. These results suggested that the expression of DDX60 might strongly associate with individualized radiosensitivity in patients with breast cancer.